CAMBRIDGE, MA--(Marketwired - January 09, 2014) -
Radius Health, Inc. ("Radius") announced today that it has strengthened its management team with the addition of John Yates, M.D., as Chief Medical Officer and Greg Williams, Ph.D., as Chief Development Officer, and the promotion of Gary Hattersley, Ph.D., to Chief Scientific Officer.
"John and Greg bring a wealth of drug development expertise and are key additions to the Radius team during a transformational time in our company's evolution and growth," said Robert Ward, President and Chief Executive Officer of Radius. "John has extensive leadership, strategic, and technical experience at the highest levels of pharmaceutical drug development in multiple therapeutic areas, including osteoporosis. We expect his leadership and his drug development experience for osteoporosis to serve Radius well as we move toward completion of the New Drug Application for BA058, or abaloparatide(1)."
Mr. Ward continued, "Greg Williams joins us in the newly created position of Chief Development Officer with a long track record of success leading drug development in both small biotechnology and large pharmaceutical companies, from preclinical through commercialization and life-cycle management. In addition, we are pleased to announce the promotion of Gary Hattersley, who has done a masterful job leading abaloparatide into clinical development and made outstanding contributions to the company's overall drug discovery and development efforts. These are highly respected scientific leaders in whom I have great confidence, and we look forward to their leadership as we continue to advance our abaloparatide injection and transdermal programs for osteoporosis and other innovative drugs we have in the pipeline for serious endocrine-mediated diseases."
John Yates, M.D., is a seasoned pharmaceutical physician-scientist leader who brings to Radius more than 30 years of experience in clinical science and pharmaceutical drug development. Prior to joining Radius, Dr. Yates was President of Global Research and Development for Takeda Pharmaceuticals, where he led the successful NDA filings of two new chemical entities and strengthened the development pipeline across multiple therapeutic areas. Prior to that, Dr. Yates served in a number of positions at Merck over a 14-year period. During that time, he led the development of the osteoporosis drug Fosamax® (alendronate) at Merck. Dr. Yates received his M.B., Ch.B. and M.D. degrees from Sheffield University Medical School, in Sheffield, UK. He gained further experience in academic medical research at the University of Melbourne, Australia and the University of Texas Health Science Center in San Antonio where his contributions included the early characterization of PTH-related protein -- the naturally occurring peptide upon which Radius' lead compound is based. Dr. Yates has authored over 70 peer-reviewed papers and 120 abstracts, with a predominant focus on disorders of bone and mineral metabolism. He has written several book chapters and invited reviews, and is an inventor on several patents.
Greg Williams, Ph.D., is a pharmaceutical industry and drug development veteran with more than 30 years of experience leading new product development, regulatory affairs, life-cycle management and commercialization for both small biotechnology and large pharmaceutical companies. Prior to joining Radius, Dr. Williams was Vice President of Regulatory Affairs, Global Product and Clinical Development, and Program Management with The Medicines Company, where he led the successful NDA and MAA filings of the IV antihypertensive drug Cleviprex®. Earlier positions include Vice President of Regulatory Affairs, Regulatory Compliance and Program Management for NPS Pharmaceuticals, where he led the successful MAA filing of the osteoporosis drug Preotact™. He has also held various management positions in clinical and drug product development for Yamanouchi Pharma America, Theraport Biosciences, GlaxoSmithKline Consumer Healthcare, and Parke-Davis Pharmaceutical. Dr. Williams has a Ph.D. in Biopharmaceutics from Rutgers University and an MBA from Cornell University.
Gary Hattersley, Ph.D., previously served as Senior Vice President, Preclinical Development at Radius. He has more than 20 years of experience in musculoskeletal research and is the author of numerous scientific publications related to bone biology and physiology. Prior to joining Radius, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals, with responsibility for the discovery and development of novel small-molecule agents for the treatment of osteoporosis and other metabolic bone diseases. Dr. Hattersley also held positions at Genetics Institute/Wyeth Research investigating the application of the bone morphogenetic proteins in bone and connective tissue repair and regeneration. Dr. Hattersley received a Ph.D. in Experimental Pathology from St. George's Hospital Medical School in London.
Abaloparatide (BA058) is a novel synthetic peptide analog of human parathyroid hormone-related protein (hPTHrP), a naturally occurring bone-building hormone, that increases bone mineral density by stimulating new bone formation. Unlike parathyroid hormone (PTH) hPTHrP is critical in the formation of the skeleton, is involved in the regulation of bone formation and is able to rebuild bone with lower associated risk of inducing the presence of too much calcium in the blood, known as hypercalcemia, as a side effect. Abaloparatide SC is in Phase 3 development as a daily self-administered injection for the treatment of patients with postmenopausal osteoporosis at high risk of fracture. Topline results from an ongoing Phase 3 pivotal trial comparing Abaloparatide SC daily injection to placebo and an active comparator for the prevention of new vertebral fractures are expected at the end of 2014. Radius is also developing Abaloparatide TD, a short wear-time transdermal patch designed to administer abaloparatide without the need for subcutaneous injection, based on 3M's patented Microstructured Transdermal System technology.
About Radius Health
Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases. The Company's lead development candidate is abaloparatide, currently in Phase 3 for the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an abaloparatide transdermal patch for osteoporosis and RAD1901 for estrogen-driven breast cancer brain metastases. www.radiuspharm.com
Safe Harbor for Forward-Looking Statements
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for Abaloparatide SC and Abaloparatide TD, clinical development plans and regulatory filings are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Radius or its management, may identify forward-looking statements. Radius cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Radius to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of Radius' proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that Radius may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Radius' business, financial conditions and results of operations are contained in Radius' filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. The forward-looking statements represent Radius' estimate as of the date hereof only, and Radius specifically disclaims any duty or obligation to update forward-looking statements.
(1) Abaloparatide is Radius' lead development candidate, currently in Phase 3 for the reduction of fracture risk in postmenopausal women with severe osteoporosis. Abaloparatide was previously referred to as BA058.